Eli Lilly's revenue nearly doubled from FY2023 to FY2025, driven by its obesity and diabetes franchise, but the stock already prices in exceptional growth at 37.7x earnings and a 117% premium to peer median EV/EBITDA. The recent $3.8B vaccine acquisition spree signals a strategic redeployment of cash flows into new therapeutic areas, yet the heavy insider selling—over 400 dispositions in 24 months—tempers enthusiasm. While momentum and improving smart-money scores are constructive, the current valuation leaves little room for execution missteps.
Valuation Compression
LLY trades at a 49% premium to peer median P/E and 164% premium on P/S; any slowdown in core franchise growth could trigger multiple contraction.
Pipeline Integration Risk
The $3.8B acquisition of three vaccine developers introduces execution risk and dilutes near-term returns on invested capital.
Insider Selling Pressure
Insiders disposed of a net 4.0M shares over 24 months, with the Lilly Endowment alone selling large blocks above $995 per share in May 2026.
Free Cash Flow Volatility
Despite surging net income, heavy capex of $7.8B in FY2025 kept free cash flow at $9.0B; a capital allocation misstep could strain returns.